{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:35Z","timestamp":1786985435209,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2024JC-YBMS-658"],"award-info":[{"award-number":["2024JC-YBMS-658"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903464"],"award-info":[{"award-number":["81903464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-YBNY-249"],"award-info":[{"award-number":["2023-YBNY-249"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bmcl.2025.130318","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:13:42Z","timestamp":1750965222000},"page":"130318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Histone deacetylase 6 inhibitors in Alzheimer's disease therapy: structure design and challenges"],"prefix":"10.1016","volume":"127","author":[{"given":"Baiyun","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bmcl.2025.130318_bb0005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3233\/JAD-2012-120727","article-title":"The role of HDAC6 in Alzheimer\u2019s disease","volume":"33","author":"Zhang","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bmcl.2025.130318_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115613","article-title":"Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases","volume":"258","author":"Han","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130318_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114090","article-title":"Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-disorders therapy","volume":"229","author":"Gu","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130318_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127023","article-title":"Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6","volume":"30","author":"Osko","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130318_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129015","article-title":"Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease","volume":"76","author":"Li","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130318_bb0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130318_bb0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molcel.2007.05.033","article-title":"HDAC6 modulates cell motility by altering the acetylation level of cortactin","volume":"27","author":"Zhang","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmcl.2025.130318_bb0040","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1126\/science.aaw9997","article-title":"Axonal transport: driving synaptic function","volume":"366","author":"Guedes-Dias","year":"2019","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130318_bb0045","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/j.1471-4159.2008.05564.x","article-title":"Histone deacetylase 6 interacts with the microtubule-associated protein tau","volume":"106","author":"Ding","year":"2008","journal-title":"J Neurochem"},{"issue":"48","key":"10.1016\/j.bmcl.2025.130318_bb0050","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1021\/acs.biochem.0c00585","article-title":"HDAC6 ZnF UBP as the modifier of tau structure and function","volume":"59","author":"Balmik","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2025.130318_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101628","article-title":"Pathophysiology of neurodegenerative diseases: an interplay among axonal transport failure, oxidative stress, and inflammation?","volume":"59","author":"Tesco","year":"2022","journal-title":"Semin Immunol"},{"issue":"6510","key":"10.1016\/j.bmcl.2025.130318_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/science.aas8995","article-title":"HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation","volume":"369","author":"Magupalli","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.bmcl.2025.130318_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115693","article-title":"Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1\u03b2 release","volume":"215","author":"Bockstiegel","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130318_bb0070","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bmcl.2025.130318_bb0075","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1158\/1078-0432.CCR-21-0238","article-title":"Wistuba, II, preclinical development and first-in-human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors","volume":"27","author":"Tsimberidou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130318_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111950","article-title":"Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: rational design, synthesis and antiproliferative activity","volume":"187","author":"Chen","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130318_bb0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/cn200100h","article-title":"Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery","volume":"3","author":"Ghose","year":"2012","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130318_bb0090","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","article-title":"A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors","volume":"103","author":"Li","year":"2024","journal-title":"Ann Hematol"},{"issue":"31","key":"10.1016\/j.bmcl.2025.130318_bb0095","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J Am Chem Soc"},{"issue":"10","key":"10.1016\/j.bmcl.2025.130318_bb0100","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/npp.2012.83","article-title":"Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats","volume":"37","author":"Hopkins","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130318_bb0105","first-page":"228","article-title":"Chlorpromazine and clothiapine actions at the level of the CNS and vas deferens","volume":"65","author":"Perez Raya","year":"1990","journal-title":"Pharm Acta Helv"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130318_bb0110","article-title":"Structure-based discovery of a small molecule inhibitor of histone deacetylase 6 (HDAC6) that significantly reduces Alzheimer\u2019s disease neuropathology","volume":"11","author":"Mondal","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.bmcl.2025.130318_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113383","article-title":"Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction","volume":"218","author":"Guo","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130318_bb0120","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1021\/acschemneuro.7b00435","article-title":"Activation of Nrf2 and hypoxic adaptive response contribute to neuroprotection elicited by phenylhydroxamic acid selective HDAC6 inhibitors","volume":"9","author":"Gaisina","year":"2018","journal-title":"ACS Chem Neurosci"},{"issue":"13","key":"10.1016\/j.bmcl.2025.130318_bb0125","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cmdc.201800156","article-title":"Benzofuran and indole: promising scaffolds for drug development in Alzheimer\u2019s disease","volume":"13","author":"Goyal","year":"2018","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130318_bb0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.bjp.0701076","article-title":"Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor","volume":"121","author":"Riendeau","year":"1997","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130318_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030829","article-title":"Carnosic acid ameliorates indomethacin-induced gastric ulceration in rats by alleviating oxidative stress and inflammation","volume":"11","author":"Danisman","year":"2023","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130318_bb0140","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/01616412.2017.1312805","article-title":"Neuroprotective effect of melatonin on soluble Abeta(1-42)-induced cortical neurodegeneration via Reelin-Dab1 signaling pathway","volume":"39","author":"Hu","year":"2017","journal-title":"Neurol Res"},{"issue":"16","key":"10.1016\/j.bmcl.2025.130318_bb0145","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1021\/acs.jmedchem.8b00151","article-title":"5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating Alzheimer\u2019s disease phenotypes","volume":"61","author":"Lee","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130318_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129148","article-title":"Discovery of indole-piperazine derivatives as selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting activities and neuroprotective activities","volume":"81","author":"Liang","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130318_bb0155","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1021\/acs.jmedchem.0c01940","article-title":"Melatonin- and ferulic acid-based HDAC6 selective inhibitors exhibit pronounced immunomodulatory effects in vitro and neuroprotective effects in a pharmacological Alzheimer\u2019s disease mouse model","volume":"64","author":"He","year":"2021","journal-title":"J Med Chem"},{"issue":"3\u20134","key":"10.1016\/j.bmcl.2025.130318_bb0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01254930","article-title":"Beta-carbolines as selective monoamine oxidase inhibitors: in vivo implications","volume":"54","author":"Glover","year":"1982","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bmcl.2025.130318_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129670","article-title":"Re-exploration of tetrahydro-beta-carboline scaffold: discovery of selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting and neuroprotective activities","volume":"102","author":"Wen","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130318_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116624","article-title":"Multimechanism biological profiling of tetrahydro-beta-carboline analogues as selective HDAC6 inhibitors for the treatment of Alzheimer's disease","volume":"275","author":"Liang","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130318_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113821","article-title":"Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer\u2019s disease","volume":"225","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"17","key":"10.1016\/j.bmcl.2025.130318_bb0180","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1021\/jm400564j","article-title":"Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer\u2019s disease","volume":"56","author":"Yu","year":"2013","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130318_bb0185","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41419-018-0688-5","article-title":"The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer\u2019s disease model","volume":"9","author":"Fan","year":"2018","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130318_bb0190","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trci.2015.08.001","article-title":"Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer\u2019s disease phenotype in amyloid precursor protein\/presenilin 1 (APP\/PS1) mice","volume":"1","author":"Majid","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"issue":"17","key":"10.1016\/j.bmcl.2025.130318_bb0195","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130318_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112887","article-title":"Mercaptoacetamide: a promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors","volume":"209","author":"Tavares","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130318_bb0205","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/acsmedchemlett.7b00012","article-title":"Design and synthesis of mercaptoacetamides as potent, selective, and brain permeable histone deacetylase 6 inhibitors","volume":"8","author":"Lv","year":"2017","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130318_bb0210","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389557519666191119144100","article-title":"Medicinal thiols: current status and new perspectives","volume":"20","author":"Pfaff","year":"2020","journal-title":"Mini Rev Med Chem"},{"issue":"18","key":"10.1016\/j.bmcl.2025.130318_bb0215","doi-asserted-by":"crossref","first-page":"12140","DOI":"10.1021\/acs.jmedchem.2c00853","article-title":"First-in-class hydrazide-based HDAC6 selective inhibitor with potent Oral anti-inflammatory activity by attenuating NLRP3 Inflammasome activation","volume":"65","author":"Yue","year":"2022","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130318_bb0220","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jpba.2010.11.007","article-title":"Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products","volume":"54","author":"Elder","year":"2011","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130318_bb0225","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/15298668691389874","article-title":"Oxidative destruction of hydrazines produces N-nitrosamines and other mutagenic species","volume":"47","author":"Castegnaro","year":"1986","journal-title":"Am Ind Hyg Assoc J"},{"issue":"19","key":"10.1016\/j.bmcl.2025.130318_bb0230","doi-asserted-by":"crossref","first-page":"13821","DOI":"10.1021\/acs.jmedchem.3c01345","article-title":"Difluoromethyl-1,3,4-oxadiazoles are selective, mechanism-based, and essentially irreversible inhibitors of histone deacetylase 6","volume":"66","author":"Konig","year":"2023","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.bmcl.2025.130318_bb0235","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1021\/acs.jmedchem.3c01269","article-title":"Selective and bioavailable HDAC6 2-(difluoromethyl)-1,3,4-oxadiazole substrate inhibitors and modeling of their bioactivation mechanism","volume":"66","author":"Ripa","year":"2023","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.bmcl.2025.130318_bb0240","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130318_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115776","article-title":"Tetrahydro-beta-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity","volume":"260","author":"Chen","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130318_bb0250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130318_bb0255","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tips.2024.05.005","article-title":"Multi-target drugs for Alzheimer's disease","volume":"45","author":"Turgutalp","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130318_bb0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s disease: targeting the cholinergic system","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.bmcl.2025.130318_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112556","article-title":"The biological activities of butyrylcholinesterase inhibitors","volume":"146","author":"Zhou","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2025.130318_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104751","article-title":"Stimulation of toll-like receptor 4 downregulates the expression of alpha7 nicotinic acetylcholine receptors via histone deacetylase in rodent microglia","volume":"138","author":"Nakamura","year":"2020","journal-title":"Neurochem Int"},{"issue":"17","key":"10.1016\/j.bmcl.2025.130318_bb0275","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1021\/acschemneuro.3c00358","article-title":"Design, synthesis, and proof of concept of balanced dual inhibitors of butyrylcholinesterase (BChE) and histone deacetylase 6 (HDAC6) for the treatment of Alzheimer\u2019s disease","volume":"14","author":"Wang","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"20","key":"10.1016\/j.bmcl.2025.130318_bb0280","doi-asserted-by":"crossref","first-page":"7901","DOI":"10.1021\/acs.jmedchem.5b00179","article-title":"Therapeutic potential of 5-HT6 receptor agonists","volume":"58","author":"Karila","year":"2015","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.bmcl.2025.130318_bb0285","doi-asserted-by":"crossref","first-page":"16533","DOI":"10.1021\/acs.jmedchem.4c01367","article-title":"Contilisant+tubastatin a hybrids: polyfunctionalized indole derivatives as new HDAC inhibitor-based multitarget small molecules with in vitro and in vivo activity in neurodegenerative diseases","volume":"67","author":"Toledano-Pinedo","year":"2024","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130318_bb0290","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/13543776.2024.2376632","article-title":"The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)","volume":"34","author":"Zhang","year":"2024","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2025.130318_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115682","article-title":"An overview of phosphodiesterase 9 inhibitors: insights from skeletal structure, pharmacophores, and therapeutic potential","volume":"259","author":"Zheng","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130318_bb0300","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1021\/acschemneuro.9b00303","article-title":"Multitarget approach for the treatment of Alzheimer\u2019s disease: inhibition of phosphodiesterase 9 (PDE9) and histone deacetylases (HDACs) covering diverse selectivity profiles","volume":"10","author":"Rabal","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmcl.2025.130318_bb0305","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejmech.2018.03.005","article-title":"Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer\u2019s disease","volume":"150","author":"Rabal","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130318_bb0310","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41386-023-01614-3","article-title":"Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry","volume":"49","author":"Hanson","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bmcl.2025.130318_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104109","article-title":"Design, synthesis and biological evaluation of dual-function inhibitors targeting NMDAR and HDAC for Alzheimer's disease","volume":"103","author":"He","year":"2020","journal-title":"Bioorg Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:08:01Z","timestamp":1762344481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25002276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":63,"alternative-id":["S0960894X25002276"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130318","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone deacetylase 6 inhibitors in Alzheimer's disease therapy: structure design and challenges","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130318"}}